Uniqure (QURE) stock soared nearly 300% on Wednesday after the Dutch biotechnology company announced a major breakthrough in Huntington’s disease. Investors are cheering QURE shares this morning because the Nasdaq-listed firm has secured new financing worth $175 million from Hercules Capital as well. More News from Barchart QURE stock is now trading roughly 460% above its year-to-date low in early April. www.barchart.com Why Did the Clinical Data Light a Fire Under QURE Stock? Uniqure shares are rall ...

"Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we highlighted and reap the gains? Cidara Therapeutics Inc. (CDTX) touched a 52-week high of $87.19 today, as it continues to progress with its accelerated development plan for CD388, a non-vaccine preventive treatment for seasonal influenza. The company will be pursuing a Biologics Licens ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Wednesday.The Dow traded down 0.35% to 46,129.26 while the NASDAQ fell 0.47% to 22,468.39. The S&P 500 also fell, dropping, 0.40% to 6,630.54.Check This Out: Top 2 Tech Stocks That May Plunge This MonthLeading and Lagging SectorsEnergy shares jumped by 1.9% on Wednesday.In trading on Tuesday, materials stocks fell by 1.5%.Top HeadlineCrude oil inventories in the U.S. declined by 0.607 million barrels i ...

U.S. equities experienced a notable pullback in afternoon trading on Wednesday, September 24, 2025, as a robust multi-day rally lost momentum. Major indexes drifted lower, with investors taking profits and digesting recent comments from Federal Reserve Chair Jerome Powell regarding elevated asset valuations. While the broader market saw a pause, specific sectors and individual stocks demonstrated significant movements, highlighting ongoing themes of artificial intelligence investment and shifting economic s ...

PresentationGood day, and welcome to the top line results for AMT-130 in Huntington's disease. [Operator Instructions] As a reminder, this call may be recorded. I would now like to turn the call over to Chiara Russo, Senior Director, Investor Relations.Chiara Russo Thank you. This morning, uniQure announced pivotal data on patients treated with our investigational gene therapy, AMT-130 in our ongoing Phase I/II clinical trials in Huntington's disease, taking place in the U.S., EU and the U.K. This 3-year u ...

Uniqure (NASDAQ: QURE) shares opened nearly 200% up on Wednesday – marking one of the most dramatic single-day moves in biotech this year. The surge follows a trifecta of bullish development: a breakt... ...

智通财经APP获悉，周三，uniQure(QURE.US)暴涨超186%，创四年新高，报39.11美元。消息面上，9 月24日，该公司宣布与Hercules Capital达成1.75亿美元非稀释性高级担保定期贷款协议，包括现有5000 万美元债务再融资，额外1.25亿美元融资可提取，利息率降至9.70%，显著改善财务灵活性。此外，该 公司公布AMT-130在亨廷顿病1/2期关键研究中达到主要终点，高剂量组36个月数据显示疾病进展减缓 75%cUHDRS测量，同时关键次要终点TFC测量显示疾病进展减缓60%。 ...

周三，uniQure(QURE.US)暴涨超186%，创四年新高，报39.11美元。消息面上，9月24日，该公司宣布 与Hercules Capital达成1.75亿美元非稀释性高级担保定期贷款协议，包括现有5000万美元债务再融资， 额外1.25亿美元融资可提取，利息率降至9.70%，显著改善财务灵活性。此外，该公司公布AMT-130在 亨廷顿病1/2期关键研究中达到主要终点，高剂量组36个月数据显示疾病进展减缓75%cUHDRS测量，同 时关键次要终点TFC测量显示疾病进展减缓60%。 ...

uniQure N.V. QURE on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington’s disease.Huntington’s disease is an inherited condition in which nerve cells in the brain break down over time. The disease affects a person’s movements, thinking ability and mental health.The study met its prespecified primary endpoint, with high-dose AMT-130 demonstrating a statistically significant slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating ...

uniQure (NasdaqGS:QURE) Update / Briefing September 24, 2025 08:30 AM ET Company ParticipantsChiara Russo - Senior Director - IRMatt Kapusta - CEO & Executive DirectorWalid Abi-Saab - Chief Medical OfficerSarah Tabrizi - ProfessorKylie O’Keefe - Chief Customer & Strategy OfficerPaul Matteis - MD & Head - Therapeutics ResearchJoseph Schwartz - Senior MD - Rare DiseasesDebjit Chattopadhyay - Senior Managing DirectorUy Ear - VP of US Healthcare - BiotechnologySalveen Richter - Biotechnology Equity ResearchElli ...